1. Home
  2. CRSP vs PHI Comparison

CRSP vs PHI Comparison

Compare CRSP & PHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • PHI
  • Stock Information
  • Founded
  • CRSP 2013
  • PHI 1928
  • Country
  • CRSP Switzerland
  • PHI Philippines
  • Employees
  • CRSP N/A
  • PHI N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • PHI Telecommunications Equipment
  • Sector
  • CRSP Health Care
  • PHI Telecommunications
  • Exchange
  • CRSP Nasdaq
  • PHI Nasdaq
  • Market Cap
  • CRSP 4.9B
  • PHI 5.0B
  • IPO Year
  • CRSP 2016
  • PHI 1953
  • Fundamental
  • Price
  • CRSP $56.26
  • PHI $19.52
  • Analyst Decision
  • CRSP Buy
  • PHI Hold
  • Analyst Count
  • CRSP 16
  • PHI 1
  • Target Price
  • CRSP $72.27
  • PHI N/A
  • AVG Volume (30 Days)
  • CRSP 1.9M
  • PHI 132.0K
  • Earning Date
  • CRSP 11-04-2025
  • PHI 11-11-2025
  • Dividend Yield
  • CRSP N/A
  • PHI 6.19%
  • EPS Growth
  • CRSP N/A
  • PHI 20.57
  • EPS
  • CRSP N/A
  • PHI 2.62
  • Revenue
  • CRSP $38,050,000.00
  • PHI $3,879,170,293.00
  • Revenue This Year
  • CRSP N/A
  • PHI $3.34
  • Revenue Next Year
  • CRSP $348.18
  • PHI $2.76
  • P/E Ratio
  • CRSP N/A
  • PHI $7.42
  • Revenue Growth
  • CRSP N/A
  • PHI 2.02
  • 52 Week Low
  • CRSP $30.04
  • PHI $19.22
  • 52 Week High
  • CRSP $71.13
  • PHI $27.93
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 54.66
  • PHI 31.93
  • Support Level
  • CRSP $51.63
  • PHI $19.36
  • Resistance Level
  • CRSP $55.59
  • PHI $19.71
  • Average True Range (ATR)
  • CRSP 2.06
  • PHI 0.48
  • MACD
  • CRSP 0.27
  • PHI -0.12
  • Stochastic Oscillator
  • CRSP 96.36
  • PHI 7.35

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About PHI PLDT Inc. Sponsored ADR

PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.

Share on Social Networks: